H.C. Wainwright Reiterates Buy Rating on Lyell Immunopharma (LYEL) Jun 3, 2026 06:55AM
Baird Starts Lyell Immunopharma (LYEL) at Outperform May 1, 2026 07:57AM
BofA Securities Reiterates Underperform Rating on Lyell Immunopharma (LYEL), PT $12, 'we continue to view the story cautiously' May 1, 2026 05:29AM
Needham Starts Lyell Immunopharma (LYEL) at Buy Apr 10, 2026 05:54AM
H.C. Wainwright Reiterates Buy Rating on Lyell Immunopharma (LYEL) Mar 23, 2026 06:48AM


Mar 16, 2026 05:02AM Citizens Reiterates Market Outperform Rating on Lyell Immunopharma (LYEL)
Mar 9, 2026 03:28AM Citizens Starts Lyell Immunopharma (LYEL) at Market Outperform
Dec 22, 2025 12:05PM Lyell Immunopharma (LYEL) halted on volatility, up 28%
Dec 9, 2025 06:16AM H.C. Wainwright Upgrades Lyell Immunopharma (LYEL) to Buy
Dec 8, 2025 02:52AM Lyell presents lymphoma trial data showing 93% response rate
Dec 5, 2025 04:39PM Lyell Immunopharma (LYEL) files for 1.9M share offering by selling stockholders
Nov 10, 2025 07:30AM Lyell Immunopharma acquires CAR T-cell therapy for colorectal cancer
Sep 26, 2025 07:17AM Lucid Capital Markets Starts Lyell Immunopharma (LYEL) at Buy
Sep 16, 2025 04:24PM Lyell Immunopharma CFO Charles Newton to resign effective October 31
Aug 12, 2025 04:52PM Lyell Immunopharma (LYEL) Files for 3.75M Share Offering by Selling Stockholders
Jul 25, 2025 08:01AM Lyell Immunopharma raises up to $100 million in private placement
Jun 24, 2025 06:48AM Lyell Immunopharma (LYEL) PT Raised to $10 at H.C. Wainwright
Jun 17, 2025 06:31AM Lyell Immunopharma (LYEL) Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314
Apr 15, 2025 09:00AM Lyell Immunopharma (LYEL) Receives RMAT Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma
Mar 13, 2025 06:47AM H.C. Wainwright Reiterates Neutral Rating on Lyell Immunopharma (LYEL)
Nov 7, 2024 04:19PM Lyell Immunopharma, Inc. (LYEL) reported Q3 Revenue
Oct 31, 2024 04:00PM Lyell Immunopharma (LYEL) Completes Acquisition of ImmPACT Bio
Oct 30, 2024 06:18AM BofA Securities Double Downgrades Lyell Immunopharma (LYEL) to Underperform
Oct 28, 2024 07:30AM H.C. Wainwright Reiterates Neutral Rating on Lyell Immunopharma (LYEL)
Oct 24, 2024 04:00PM Lyell Immunopharma (LYEL) to Acquire ImmPACT Bio, Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
Jun 26, 2024 07:02AM Lyell Immunopharma (LYEL) Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797